|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Tasisulam
|
MedKoo Code#: 202851
|
|
Name: Tasisulam
|
|
CAS#:
519055-62-0
Synonym: LY573636-sodium;
benzamide, N-[(5-bromo-2-thienyl)sulfonyl]-2,4-dichloro-, sodium
salt
IUPAC/Chemical name:
sodium ((5-bromothiophen-2-yl)sulfonyl)(2,4-dichlorobenzoyl)amide
|
|
Chemical structure: |
Theoretical analysis
|
|
|
Tasisulam:
Chemical Formula: C11H6BrCl2NO3S2 Exact Mass:
412.83495
Molecular Weight: 415.11
m/z: 412.83495 (100.0%), 414.83291 (97.3%),
414.83200 (63.9%), 416.82996 (62.2%).
Elemental Analysis: C, 31.83; H, 1.46;
Br, 19.25; Cl, 17.08; N, 3.37; O, 11.56; S, 15.45
Tasisulam sodium:
Chemical Formula: C11H5BrCl2NNaO3S2 Molecular
Weight: 437.q
Elemental Analysis: C, 30.23; H, 1.15; Br,
18.28; Cl, 16.22; N, 3.20; Na, 5.26; O, 10.98; S, 14.67
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
Tasisulam sodium is The sodium salt of an acyl-sulfonamide
with potential antineoplastic activity. Selectively toxic towards tumor
cells, tasisulam appears to induce tumor cell apoptosis by a
mitochondrial-targeted mechanism involving the loss of mitochondrial
membrane potential and induction of reactive oxygen species (ROS). In
combination with an angiogenesis inhibitor, this agent may exhibit
synergistic antiangiogenic activity. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer: Eli Lilly
1. Yates, Matthew H.; Kallman, Neil J.; Ley,
Christopher P.; Wei, Jeffrey N. Development of an Acyl Sulfonamide
Anti-Proliferative Agent, LY573636 Na. Organic Process Research &
Development (2009), 13(2), 255-262. CODEN: OPRDFK ISSN:1083-6160. CAN
150:262410 AN 2009:44896
2. Haritunians, Talin; Gueller, Saskia; O'Kelly, James; Ilaria, Robert,
Jr.; Koeffler, H. Phillip. Novel acyl sulfonamide LY573636-sodium:
effect on hematopoietic malignant cells. Oncology Reports (2008), 20(5),
1237-1242. CODEN: OCRPEW ISSN:1021-335X. CAN 150:389379 AN 2008:1429431
3. Semba, Taro. Novel marker for sensitivity against sulfonamide
compound. PCT Int. Appl. (2007), 82pp. CODEN: PIXXD2 WO 2007123274 A1
20071101 CAN 147:462224 AN 2007:1237479
4. Ozawa, Yoichi. Method for prediction of the effect of sulfonamide
compound. PCT Int. Appl. (2007), 57pp. CODEN: PIXXD2 WO 2007086605 A1
20070802 CAN 147:203891 AN 2007:845823
5. Owa, Takashi; Ozawa, Yoichi; Semba, Taro; Wakabayashi, Toshiaki.
Novel combinational use of sulfonamide compound. PCT Int. Appl. (2006),
128pp. CODEN: PIXXD2 WO 2006090930 A1 20060831 CAN 145:263277 AN
2006:888397
6. Owa, Takashi; Ozawa, Yoichi; Ono, Naoto. Inhibitory effect of
sulfonamide compound on lymphocyte activation. PCT Int. Appl. (2006),
60pp. CODEN: PIXXD2 WO 2006090921 A1 20060831 CAN 145:263294 AN
2006:887145
7. Owa, Takashi; Ozawa, Yoichi; Ono, Naoto. Orexigenic action of
sulfonamide compound. PCT Int. Appl. (2006), 58pp. CODEN: PIXXD2 WO
2006090927 A1 20060831 CAN 145:263326 AN 2006:885745
8. Owa, Takashi; Ozawa, Yoichi; Semba, Taro; Hata, Naoko. Novel
concomitant use of sulfonamide compound with anti-cancer agent. PCT Int.
Appl. (2006), 96pp. CODEN: PIXXD2 WO 2006090931 A1 20060831 CAN
145:263273 AN 2006:884431
9. Semba, Taro; Hata, Naoko; Ozawa, Yoichi; Owa, Takashi. Novel use of
sulfonamide compound in combination with angiogenesis inhibitor. PCT
Int. Appl. (2006), 88pp. CODEN: PIXXD2 WO 2006090928 A1 20060831 CAN
145:263272 AN 2006:884352
10. Owa, Takashi; Yokoi, Akira; Ozawa, Yoichi; Kawai, Takatoshi;
Ushijima, Rie. Development of a method to evaluate the sensitivity of
tumor cells to sulfonamide containing compounds by gene expressing
profiling. PCT Int. Appl. (2006), 1405 pp. CODEN: PIXXD2 WO 2006036025
A1 20060406 CAN 144:388497 AN 2006:317422
11. Owa, Takashi; Ozawa, Yoichi; Semba, Taro. Simultaneous use of
sulfonamide-containing compound and angiogenesis inhibitor. PCT Int.
Appl. (2006), 270 pp. CODEN: PIXXD2 WO 2006030941 A1 20060323 CAN
144:324798 AN 2006:268466
12. Mader, Mary M.; Shih, Chuan; Considine, Eileen; De Dios, Alfonso;
Grossman, Cora Sue; Hipskind, Philip A.; Lin, Ho-Shen; Lobb, Karen L.;
Lopez, Beatriz; Lopez, Jose E.; Cabrejas, Luisa M. Martin; Richett,
Michael E.; White, Wesley T.; Cheung, Yiu-Yin; Huang, Zhongping; Reilly,
John E.; Dinn, Sean R. Acyl sulfonamide anti-proliferatives. Part 2:
Activity of heterocyclic sulfonamide derivatives. Bioorganic & Medicinal
Chemistry Letters (2005), 15(3), 617-620. CODEN: BMCLE8 ISSN:0960-894X.
CAN 142:316746 AN 2005:74670
13. De Dios, Alfonso; Grossman, Cora Sue; Hipskind, Philip Arthur; Lin,
Ho-Shen; Lobb, Karen Lynn; Lopez de Uralde Garmendia, Beatriz; Lopez,
Jose Eduardo; Mader, Mary Margaret; Richett, Michael Enrico; Shih, Chaun.
Preparation of thiophene- and thiazolesulfonamides as antineoplastic
agents. PCT Int. Appl. (2003), 54 pp. CODEN: PIXXD2 WO 2003035629 A1
20030501 CAN 138:353973 AN 2003:335090
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
